Antitumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models

Abstract

Angiogenesis mediated by vascular endothelial growth factor superiority to bevacizumab in the inhibition of VEGF-A binding (VEGF) is a hallmark of glioblastoma. Based on the response rate to VEGF receptor (VEGFR) 1 in enzyme-linked immunosorbent and improved progression-free survival, although not on overall assay by a factor of around 10 and comparable efficacy for the survival, the 149-kDa anti-VEGF-A IgG antibody bevacizumab inhibition of VEGF-A-stimulated VEGFR2 dimerization. In a tube-(Avastin) has been approved in the United States and Japan for formation assay with human cerebral microvascular endothelial recurrent glioblastoma and in Japan for newly diagnosed cells, DLX1008 was at least as active as bevacizumab. In vivo, glioblastoma; however, it is not approved in the EU. Here we DLX1008 delayed growth in a mouse subcutaneous U87 characterize the biologic activity of DLX1008, a 26-kDa anti-xenograft model (P 5 0.0021) and improved survival in a mouse VEGF-A single-chain antibody fragment that shows 30-fold orthotopic U87 xenograft model (P 5 0.00026). Given the stronger affinity to human VEGF-A than bevacizumab. The small exceptionally high affinity and small molecular size of molecular size of DLX1008 is predicted to result in improved DLX1008, these data warrant further clinical development of target coverage over bevacizumab. DLX1008 showed DLX1008 as an antiangiogenic agent in glioblastoma.